



Anbesol Products

Preparation Date 22-Jun-2007

Revision Date Not applicable

Revision Number Not applicable

**1. PRODUCT AND COMPANY IDENTIFICATION**

**Product Name** Anbesol Products  
**Common Name** Not available  
**Chemical Name** Not applicable  
**Synonyms** Baby Anbesol, Anbesol Jr., Anbesol Regular Strength, Anbesol Maximum Strength, Anbesol Cold Sore Therapy  
**Product Use Classification** Pharmaceutical product  
Local Anesthetic  
**Supplier** Wyeth  
P.O. Box 8299  
Philadelphia, PA 19101 USA.  
Telephone: 1-610-688-4400

**Emergency Telephone Number** Chemtrec USA, Puerto Rico, Canada 1-800-424-9300  
Chemtrec International 1-703-527-3887

**2. HAZARDS IDENTIFICATION**

**Emergency Overview**

This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

**Appearance** Pharmaceutical liquid or gel      **Physical State** Liquid      **Odor** Odorless

**Potential Physical Hazards** None known

**Potential Health Effects**

**Eyes** May cause irritation  
**Skin** The most common effects may include allergic reactions, local numbness and Irritation.  
Please see Product Insert for further information.  
**Inhalation** Not available  
**Ingestion** No data available  
**Therapeutic Target Organ(s)** Skin

Not listed by OSHA, NTP or IARC.

**Potential Environmental Effects** There is no known ecological information for this product.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Common Name	CAS-No	Composition
Petrolatum	8009-03-08	0-65%

Common Name	CAS-No	Composition
Benzocaine	94-09-7	7.5-20%
Allantoin	97-59-6	0-1%
Camphor	76-22-2	0-3%
Inactive Ingredients	Not applicable	Remainder

#### 4. FIRST AID MEASURES

<b>Eye Contact</b>	In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.
<b>Skin Contact</b>	Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
<b>Inhalation</b>	Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.
<b>Ingestion</b>	If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

#### 5. FIRE-FIGHTING MEASURES

<b>Flammable Properties</b>	Not flammable.
<b>Extinguishing Media</b>	
<b>Suitable Extinguishing Media</b>	Use water spray, foam, dry chemical or carbon dioxide.
<b>Unsuitable Extinguishing Media</b>	Do NOT use water jet.
<b>Fire Fighting</b>	Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.
<b>Hazardous Combustion Products</b>	Carbon oxides, nitrogen oxides.
<b>Protective Equipment and Precautions for Firefighters</b>	In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

#### 6. ACCIDENTAL RELEASE MEASURES

<b>Personal Precautions</b>	Refer to protective measures listed in Sections 7 and 8.
<b>Environmental Precautions</b>	Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.
<b>Methods for Containment</b>	Not available
<b>Methods for Cleaning up</b>	Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.

#### 7. HANDLING AND STORAGE

<b>Handling</b>	For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.
<b>Storage</b>	No special safety precautions required. Keep container tightly closed.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<b>Common Name</b>	<b>Exposure Guideline</b>
Benzocaine	500 mcg/m <sup>3</sup>
Camphor	2 mg/m <sup>3</sup> PEL (OSHA)
Inactive Ingredients	250 mg/m <sup>3</sup>
<b>Engineering Controls</b>	No special precautions required
<b>Personal Protective Equipment</b>	
<b>Eye/face Protection</b>	Avoid contact with skin and eyes
<b>Skin Protection</b>	For prolonged or repeated exposure use protective gloves. No special protective clothing required under typical conditions of use.
<b>Respiratory Protection</b>	No personal respiratory protective equipment normally required.
<b>General Hygiene Considerations</b>	When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands before breaks and at the end of workday.
<b>Other</b>	Not available

## 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Appearance</b>	Pharmaceutical liquid or gel	<b>Physical State</b>	Liquid
<b>Color</b>	Various	<b>Odor</b>	Odorless
<b>Odor Threshold</b>	Not available		
<b>pH</b>	Not available		
<b>Specific Gravity</b>	Not applicable	<b>Water Solubility</b>	Soluble in water
<b>Solubility</b>	Not available	<b>Evaporation Rate</b>	Not applicable
<b>Partition Coefficient (n-octanol/water)</b>	Not available	<b>Vapor Pressure</b>	Not applicable
<b>Boiling Point</b>	Not available	<b>Autoignition Temperature</b>	Not applicable
<b>Flash Point</b>	Not available	<b>Method</b>	None
<b>Melting Point</b>	Not applicable		
<b>Flammability Limits in Air</b>	<b>Upper</b> Not applicable	<b>Lower</b> Not applicable	
<b>Explosion Limits</b>	<b>Upper</b> Not applicable	<b>Lower</b> Not applicable	

## 10. STABILITY AND REACTIVITY

<b>Chemical Stability</b>	Stable at room temperature.
<b>Conditions to Avoid</b>	No data available
<b>Materials to Avoid</b>	No materials to be especially mentioned.
<b>Hazardous Decomposition Products</b>	None under normal use.
<b>Possibility of Hazardous Reactions</b>	None under normal use.

## 11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

### Acute Toxicity

#### Benzocaine

LD50 Oral	3042 mg/kg rats
Acute Dermal Irritation	Mild irritation effect in guinea pigs.
Primary Eye Irritation	Not available
Sensitization	Not available

### Multiple Dose Toxicity

#### Maximum Tolerated Dose (MTD), Oral

## 12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Chemical Fate Information Not available

Ecotoxicity Not available

## 13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

## 14. TRANSPORT INFORMATION

Transport Information This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT)	Not regulated
Canadian Transport of Dangerous Goods (TDG)	Not regulated
International Civil Aviation Organization (ICAO)	Not regulated
International Air Transport Association (IATA)	Not regulated
International Maritime Dangerous Goods (IMDG)/International Maritime Organization (IMO)	Not regulated
Transport of Dangerous Goods by Rail (RID)	Not regulated
Transport of Dangerous Goods by Road (ADR)	Not regulated
Transportation of Dangerous Goods via Inland Waterways (ADN)	Not regulated

## 15. REGULATORY INFORMATION

### USA

#### Federal Regulations

**OSHA Regulatory Status**

This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

**SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

**SARA 311/312 Hazardous Categorization**

<b>Acute Health Hazard</b>	No
<b>Chronic Health Hazard</b>	No
<b>Fire Hazard</b>	No
<b>Sudden Release of Pressure Hazard</b>	No
<b>Reactive Hazard</b>	No

This product does not contain any HAPs.

**State Regulations****California Proposition 65**

This product does not contain any Proposition 65 chemicals.

**Canada**

Not classified

**WHMIS Hazard Class**

Non-controlled

**European Union**

In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

## 16. OTHER INFORMATION

<b>Prepared By</b>	Wyeth Department of Environment, Health & Safety
<b>Format</b>	This MSDS was prepared in accordance with ANSI Z400.1-2004.
<b>List of References</b>	See Patient Package Insert for more information.
<b>Revision Summary</b>	No changes

## Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

**End of MSDS**